Entresto uptake forecast to fuel heart failure market's 15.7% CAGR

The heart failure space across the seven key markets of the USA, France, Germany, Italy, Spain, the UK and Japan is set to grow from $3.7 billion in 2016 to around $16.1 billion by 2026, representing an impressive compound annual growth rate (CAGR) of 15.7%.

According to research and consulting firm GlobalData’s latest report, the strongest driver of this rise in market value will be the growing uptake of Swiss pharma giant Novartis’ (NOVN: VX) Entresto (sacubitril/valsartan) over the forecast period, despite initial modest sales. Other drivers will include the launch of several chronic heart failure therapies, including Amgen (Nasdaq: AMGN) and Cytokinetics’ (Nasdaq: CYTK) omecamtiv mecarbil, and an increase in the global prevalence of chronic heart failure and incidence of acute heart failure.

Elizabeth Hamson, healthcare analyst for GlobalData, explains: “Over the past two decades, chronic heart failure therapies have demonstrated success in slowing the progression of the disease and in reducing both mortality and morbidity in large-scale clinical trials. However, these successes have been limited to heart failure with reduced ejection fraction (HF-REF), showing only moderate benefits in heart failure with preserved ejection fraction (HF-PEF). Despite the lack of strong clinical evidence, guideline-recommended HF-REF therapies are widely used to treat HF-PEF.”